20/20 Biolabs, Inc. AIDX

Company Overview

Publicly available corporate and market records do not clearly verify that “20/20 Biolabs, Inc.” is the operating company associated with the ticker symbol “AIDX.” Multiple major market data providers and exchange references associate “AIDX” with Ainos, Inc., a healthcare technology and biotechnology company focused on point-of-care testing, low-dose interferon therapeutics, and AI-driven scent digitization technologies. Because of this discrepancy, data regarding “20/20 Biolabs, Inc. (AIDX)” is inconclusive based on available public sources.

Based on publicly available SEC and exchange-related information tied to Ainos, Inc., the company operates in the healthcare diagnostics and biotechnology sectors, with activities involving rapid testing technologies, therapeutic research, and emerging AI-enabled sensory applications. Reported business initiatives have included healthcare diagnostics, antiviral-related technologies, and digital scent platforms intended for robotics and smart-device integration. Historical records indicate the company has undergone corporate restructuring and strategic repositioning over time, including shifts in branding and technology focus.